Advertisement
Loading...

Akari Therapeutics, Plc

AKTX•NASDAQ
Healthcare
Biotechnology
$18.27
$13.13(255.45%)
U.S. Market opens in 30h 27m

Akari Therapeutics, Plc (AKTX) Stock Overview

Explore Akari Therapeutics, Plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap20.9M
P/E Ratio-0.00
EPS (TTM)$-2.58
ROE-1.23%
Fundamental Analysis

AI Price Forecasts

1 Month$0.41
3 Months$0.92
1 Year Target$0.00

AKTX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Akari Therapeutics, Plc (AKTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 85.00, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.00 and a market capitalization of 20.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
255.45%
5-Day Change
393.78%
1-Month Change
215.54%
3-Month Change
93.13%
6-Month Change
1.50%
Year-to-Date (YTD) Change
58.04%
1-Year Change
-63.46%
3-Year Change
-88.75%
5-Year Change
-98.74%
All-Time (Max) Change
-99.86%

Contact Information

https://www.akaritx.com
44 20 8004 0270
75/76 Wimpole Street, London, FL, W1G 9RT

Company Facts

8 Employees
IPO DateJan 6, 2014
CountryGB
Actively Trading

Frequently Asked Questions